They demonstrated the applicability of the Simoa platform for nucleic acid detection, and miRNA detection in particular, as Quanterix prepares to launch a new system.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.
